Puma Biotechnology, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$38.7M
Doctors Paid
9,190
Transactions
37,663
2024 Total
$3.5M
Payment Breakdown by Category
Research$31.0M (80.1%)
Consulting$3.6M (9.3%)
Food & Beverage$801,763 (2.1%)
Travel$610,940 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $31.0M | 1,887 | 80.1% |
| Consulting Fee | $3.6M | 969 | 9.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 818 | 6.0% |
| Food and Beverage | $801,763 | 31,188 | 2.1% |
| Travel and Lodging | $610,940 | 2,465 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $314,339 | 132 | 0.8% |
| Grant | $10,000 | 1 | 0.0% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $5,897 | 7 | 0.0% |
| Education | $2,102 | 196 | 0.0% |
Payments by Type
Research
$31.0M
1,887 transactions
General
$7.7M
35,776 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION | $4.6M | 0 | 300 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NERATINIB (HKI-272) AFTER TRASTUZUMAB IN WOMEN WITH EARLY-STAGE HER-2/NEU OVEREXPRESSED/AMPLIFIED BREAST CANCER | $1.7M | 3 | 112 |
| AN OPEN-LABEL, PHASE 2 BASKET STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC ACTIVATING HER MUTATIONS | $1.7M | 0 | 72 |
| An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors | $1.7M | 0 | 115 |
| An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal | $1.6M | 0 | 86 |
| An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early | $1.6M | 0 | 54 |
| . | $1.4M | 0 | 11 |
| THIS IS AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, MULTINATIONAL, PHASE 2 STUDY | $1.2M | 0 | 119 |
| A STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (ALISCA-LUNG1) | $1.1M | 0 | 177 |
| An Open?Label Study to Characterize the Incidence and Severity of Diarrhea | $1.0M | 0 | 105 |
| BASKET STUDY OF NERATINIB IN PARTICIPANTS WITH SOLID TUMORS HARBORING SOMATIC HER2 OR EGFR EXON 18 MUTATIONS (SUMMIT) | $911,655 | 0 | 9 |
| A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated | $805,972 | 0 | 1 |
| AN OPEN LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION | $756,293 | 0 | 43 |
| AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA | $712,730 | 0 | 34 |
| AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA IN PATIENTS WITH EARLY-STAGE HER2+ BREAST CANCER TREATED WITH NERATINIB AND INTENSIVE LOPERAMIDE PROPHYLAXIS | $630,803 | 0 | 39 |
| A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ | $523,614 | 0 | 36 |
| A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer | $476,857 | 0 | 1 |
| A Phase II Study of Neratinib alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer | $363,238 | 0 | 2 |
| PHASE I STUDY OF THE PAN-ERBB INHIBITOR NERATINIB GIVEN IN COMBINATION WITH EVEROLIMUS, PALBOCICLIB, OR TRAMETINIB IN ADVANCED CANCER SUBJECTS WITH EGFR MUTATION/AMPLIFICATION, HER2 MUTATION/AMPLIFICATION, OR HER3/4 MUTATION OR KRAS MUTATION | $349,363 | 0 | 2 |
| AN OPEN LABEL, PHASE II TRIAL OF PRE-OPERATIVE NERATINIB AND ENDOCRINE THERAPY WITH TRASTUZUMAB IN TRIPLE POSITIVE BREAST CANCERS HCRN-BRE17-141 | $325,650 | 0 | 7 |
| A Study of Neratinib Plus Capecitabine versus Lapatinib Plus Capecitabine(NALA) | $301,426 | 0 | 56 |
| ALISERTIB WITH OR WITHOUT FULVESTRANT IN TREATING PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ENDOCRINE RESISTANT BREAST CANCER | $299,864 | 0 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib | $298,949 | 1 | 124 |
| A PHASE 2 STUDY OF NERATINIB WITH OR WITHOUT FULVESTRANT IN HER2-POSITIVE, ER-POSITIVE METASTATIC BREAST CANCER | $293,466 | 0 | 3 |
| A Study of Neratinib Plus Capecitabine versus Lapatinib Plus Capecitabine in Patients with HER2+ | $286,452 | 0 | 115 |
| IMPACT Profiling in Patients with Advanced Cervix Cancer | $275,250 | 0 | 7 |
| A PHASE II TRIAL OF HKI-272 (NERATINIB), NERATINIB AND CAPECITABINE, AND ADO-TRASTUZUMAB EMTANSINE FOR PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER AND BRAIN METASTASES | $256,160 | 0 | 2 |
| A PHASE II STUDY OF ALISERTIB, AN INVESTIGATIONAL DRUG, IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) | $253,935 | 0 | 13 |
| A STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER (ALISCA-BREAST1) | $253,397 | 0 | 14 |
| Evaluating Neratinib in orthotopic PDX models of breast cancer brain metastases | $232,418 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Martin Dietrich, M.d., Ph.d, M.D., PH.D | Student in an Organized Health Care Education/Training Program | Rockledge, FL | $45,822 | $0 |
| Linda Bosserman, M.d., F.a.c.p, M.D., F.A.C.P | Internal Medicine | Duarte, CA | $45,472 | $0 |
| Stefan Gluck, Md, MD | Hematology & Oncology | Miami, FL | $45,015 | $0 |
| Dr. Cristina Truica, M.d, M.D | Hematology & Oncology | Hershey, PA | $44,681 | $0 |
| Mrs. Reshma Mahtani, D.o, D.O | Hematology & Oncology | Plantation, FL | $40,616 | $0 |
| Dr. Lauren Carcas, M.d, M.D | Internal Medicine | Plantation, FL | $39,636 | $0 |
| Jack Dipalma, Md, MD | Gastroenterology | Mobile, AL | $38,433 | $0 |
| Fadi Braiteh, M.d, M.D | Internal Medicine | Las Vegas, NV | $37,738 | $0 |
| Misagh Karimi, Md, MD | Hematology & Oncology | Newport Beach, CA | $36,891 | $0 |
| Garry Schwartz, Md, MD | Internal Medicine | Albemarle, NC | $36,790 | $0 |
| Ralph Boccia, M.d, M.D | Medical Oncology | Bethesda, MD | $36,645 | $0 |
| Claudine Isaacs | Hematology & Oncology | Washington, DC | $34,092 | $0 |
| Ruta Rao, M.d, M.D | Medical Oncology | Chicago, IL | $33,510 | $0 |
| Dr. Joyce O'shaughnessy, Md, MD | Medical Oncology | Dallas, TX | $32,280 | $0 |
| Dr. Sayeh Lavasani, Md, MD | Medical Oncology | Orange, CA | $31,714 | $0 |
| Dr. Andrew Muskovitz, M.d, M.D | Hematology & Oncology | Southfield, MI | $31,440 | $0 |
| Unknown Provider | — | — | $27,737 | $0 |
| Dr. Timothy Pluard, Md, MD | Medical Oncology | Kansas City, MO | $24,213 | $0 |
| Dr. Irene Kang, M.d, M.D | Internal Medicine | Irvine, CA | $23,827 | $0 |
| Dr. Nitin Rohatgi, M.d, M.D | Hematology | Sacramento, CA | $23,623 | $0 |
| Victoria Poillucci, Np, NP | Nurse Practitioner | Raleigh, NC | $22,065 | $0 |
| Milana Dolezal, M.d, M.D | Hematology | Palo Alto, CA | $21,728 | $0 |
| Cynthia Bedell, Msn, Rn, Anp-C, MSN, RN, ANP-C | Adult Health | Dallas, TX | $21,259 | $0 |
| Dr. Hope Rugo, Md, MD | Internal Medicine | San Francisco, CA | $20,805 | $0 |
| Kumar Abhishek, M.d, M.D | Internal Medicine | Mechanicsville, VA | $20,271 | $0 |
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc. has made $38.7M in payments to 9,190 healthcare providers, recorded across 37,663 transactions in the CMS Open Payments database. In 2024, the company paid $3.5M. The top product by payment volume is NERLYNX ($19.9M).
Payments were distributed across 144 medical specialties. The top specialty by payment amount is Medical Oncology ($3.2M to 716 doctors).
Payment categories include: Food & Beverage ($801,763), Consulting ($3.6M), Research ($31.0M), Travel & Lodging ($610,940).
Puma Biotechnology, Inc. is associated with 2 products in the CMS Open Payments database.